An Investor’s Guide to Merck & Co.'s Earnings in 2Q15 (Continued from Prior Part) Geographical performance Merck & Co. (MRK) operates in over 140 countries worldwide through its more than 450 ...

Broader Portfolio, Robust Late-Stage Pipeline and Expanded Geographic Presence Position Merck for LeadershipEmerging Markets Expected to Account for More Than 25 Percent of Merck's Pharmaceutical and ...

Merck & Co Inc (NYSE:MRK) recently announced a dividend of $0.77 per share, payable on 2024-01-08, with the ex-dividend date set for 2023-12-14. As investors look forward to this upcoming payment ...

Merck, based in Darmstadt, last week reported 2009 earnings of euro366 million ($498.7 million), nearly unchanged from 2008. The company, which makes the cancer drug Erbitux, multiple sclerosis ...

Standalone company positioned to deliver low to mid-single digit revenue growth off 2021 base Future growth opportunities include Women’s Health and Biosimilars businesses; Established Brands ...

From a geographical perspective, just under half of the company's sales are generated in the United States. Having examined the options trading patterns of Merck & Co, our attention now turns ...

As Merck moves forward with plans to close their Riverside facility, the company remains committed to its West Point location and other sites, writes Nathan Owens for Manufacturing Drive. The ...

Merck & Co (NYSE:MRK) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The following table summarizes their recent ratings ...

Below, we present a snapshot of the trends in volume and open interest for calls and puts across Merck & Co's significant trades, within a strike price range of $40.0 to $110.0, over the past month.

Merck & Co., Inc. MRK is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum of $1.3 billion.This acquisition is expected to significantly expand Merck’s presence in the ...

Merck and Bristol-Myers Squibb to end co-promotion of Erbitux in Japan, with full promotional responsibilities transferring to Merck "Expanding our oncology presence in Japan is of strategic ...